Why You Can't Sleep — And What the Science Says About THC, CBD, and CBG

By Jesse Cole Christianson, DNP, APRN, AGPCNP-BC | cannabisdnp.com

Educational only. Not medical advice. These statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

If you've ever lain awake at 2 a.m. with a racing mind and an exhausted body, you already understand what researchers now confirm clinically: insomnia isn't a sleep problem. It's a brain arousal problem. The circuits that are supposed to power down stay stubbornly active — and that distinction matters enormously for how we think about solutions.

About 30% of U.S. adults experience insomnia symptoms. Chronic insomnia — difficulty falling or staying asleep at least three nights per week for three or more months — affects roughly 10–15% of the population. It's one of the most common and most undertreated conditions in primary care.

The two systems that control sleep — and why one gets stuck

Your brain manages sleep through two parallel systems. The first is your circadian rhythm — a 24-hour internal clock driven by light and darkness. The second is sleep pressure: as the chemical adenosine accumulates throughout your waking hours, the urge to sleep builds until it becomes undeniable.

Insomnia hijacks neither of these directly. Instead, it overactivates the locus coeruleus (LC) — the brain's primary source of noradrenaline. In the central nervous system, noradrenaline transmission controls the degree to which we are awake, alert, and attentive, and action potential firing of the noradrenaline neurons in the locus coeruleus drives the transition from sleep to wake. The norepinephrine locus coeruleus system represents a promising treatment target in patients with insomnia disorder due to its well-understood links to arousal and sleep regulation.

In people with insomnia, this system stays locked in overdrive. That's exactly where cannabinoids have something clinically interesting to offer — and why dose precision isn't optional.

Three cannabinoids. Three brain targets. One important rule about dose.

The same cannabinoid at the wrong dose can produce the exact opposite of the effect you're seeking. This isn't a footnote — it's the whole game. Think of it this way: the molecule is the key, but the dose is the lock. And your first dose is a trial — not a verdict.

Too many people try a cannabinoid once at a random amount, get an unexpected result, and conclude it doesn't work for them. What they actually ran was an uncontrolled experiment with an unknown variable. Dose, timing, and formulation all determine the outcome. Here's what the data actually show.

Δ9-THC and the CB1 pathway

THC acts on CB1 receptors concentrated in the hypothalamus, the brain region governing the sleep-wake switch. By modulating this circuit, THC helps turn down the physiological drive toward wakefulness.

The evidence is compelling. In a systematic review and meta-analysis of six RCTs involving 1,077 patients, investigators examined the efficacy of at least one week of cannabinoid therapy on sleep quality. Cannabinoid-based interventions were associated with improvements in sleep quality, and treatments incorporating THC were associated with a significant improvement in subjective sleep assessments compared with placebo. In one crossover RCT, 60% of chronic insomnia patients no longer qualified as having insomnia after just two weeks of THC+CBD.

On dose: At 10–20 mg, multiple RCTs show reduced sleep-onset latency and improved subjective sleep quality. At 20–30 mg, the picture shifts: slow-wave (deep) sleep deepens and REM sleep decreases. For most people, less REM sounds like a drawback — and long-term it warrants monitoring. But for patients with PTSD-related nightmares, this is precisely the mechanism of benefit. Nightmares occur during REM. A reduction in REM duration and intensity means fewer opportunities for the nightmare cycle to run. This is the leading neurobiological theory for why THC-based therapies show meaningful results in PTSD sleep studies — not sedation, but targeted REM suppression at the right dose. Above 30 mg, next-day sedation, cognitive fog, and tolerance accumulation become real clinical concerns. The goal is therapeutic, not just sedating. Source: Luu et al., Sleep Medicine Reviews, 2025.

CBD and the adenosine pathway

CBD's mechanism is distinct from THC's. Rather than acting on the sleep-wake switch directly, CBD enhances the activity of adenosine — your brain's natural sleep-pressure chemical. The more adenosine available to do its job, the stronger the biological signal to sleep.

In a double-blind RCT of 1,793 adults with sleep disturbance symptoms, participants received a 4-week supply of products containing CBD alone or in combination with minor cannabinoids, and sleep disturbance was assessed using validated patient-reported outcome measures. Combinations consistently outperformed single-ingredient approaches.

On dose: CBD is biphasic — and this trips people up more than any other variable in cannabinoid therapeutics. At low doses (roughly ≤25 mg), CBD can be mildly alerting, not calming. Someone who tries it at a low dose, gets no sleep benefit, and concludes "CBD doesn't work" may have been on the wrong side of the dose curve the entire time. Remember: your first dose is a trial, not a verdict.

For calming and sleep-supportive effects, the research points toward a target range of approximately 10–20 mg/kg/day — meaning a 70 kg (154 lb) person would be looking at roughly 700–1,400 mg daily to reach the full anxiolytic and sleep-promoting threshold studied in clinical trials. That's a high bar for most consumer products, and pricey. The practical takeaway: at the doses found in most hemp edibles, CBD is playing a supporting role — enhancing the entourage effect alongside THC and CBG — rather than carrying the full therapeutic load solo. This is exactly why precision combination formulation matters. Source: Blessing et al., Neurotherapeutics, 2015; Shannon et al., The Permanente Journal, 2019.

At therapeutic research doses, CBD's calming effects are well-documented — a large retrospective case series published in The Permanente Journal found that 79.2% of patients reported decreased anxiety scores and 66.7% reported improved sleep scores within the first month of CBD use, with sustained improvement in most cases.

CBG and the alpha-2 adrenergic pathway

CBG is the newest entrant — and its mechanism is exactly what insomnia researchers have been looking for. A 2023 peer-reviewed study in Frontiers in Pharmacology examined CBG's effects on locus coeruleus neurons. CBG has been reported to target α2-adrenoceptors and 5-HT1A receptors, with the locus coeruleus and dorsal raphe nucleus being the main noradrenergic and serotonergic areas studied. Investigators observed that CBG regulates α2-adrenoceptor-mediated inhibitory responses on neuronal activity of locus coeruleus cells, and the compound produced anxiolytic-like effects through the 5-HT1A receptor.

Aberrant locus coeruleus activity is implicated in sleep disorders such as insomnia, and pharmacological treatments, including the α2-adrenergic agonist clonidine, function by reducing tonic locus coeruleus activity. CBG appears to access this same pathway — without the hypotension and rebound risks of pharmaceutical alpha-2 agonists. A Veterans Affairs clinical trial is currently underway evaluating CBG for sleep.

On dose: The precise active range is still being characterized in ongoing trials. 20mg has been the frontrunner to decrease anxiety, which can help with relaxation. What pharmacology makes clear is that receptor-level precision matters here just as much as with THC and CBD. Your first dose is a trial — track how you feel, adjust methodically, and give it consistent timing before drawing conclusions.

Why combination and format both matter

THC quiets the hypothalamic wake-drive. CBD builds adenosine sleep pressure and complements THC's receptor activity at combination doses. CBG damps the locus coeruleus alert system. Stack myrcene and linalool on top — both modulate GABA-A activity — and you have a multi-pathway approach that mirrors how the endocannabinoid system naturally supports the sleep transition.

Timing matters too. Edibles have a delayed onset — typically 30 to 90 minutes depending on metabolism and food intake. Taking too late and the peak effect arrives after your optimal sleep window has closed. The practical guidance: 30–60 minutes before bed, consistently, to establish predictable pharmacokinetics.

This is also where production format becomes clinically relevant. Standard gummy manufacturing uses high-temperature processes that degrade terpenes — volatile compounds essential to the entourage effect. Dr. Murse Therapeutic Taffies are produced at lower temperatures, preserving the complementary terpene profiles that amplify cannabinoid receptor activity. That's not marketing language — it's thermochemistry.

What to keep in mind

Few studies have examined the efficacy of cannabinoids in the treatment of insomnia disorder, and heterogeneity of participants, interventions, and outcomes does not yet reliably inform evidence-based practice at a population level. The research is promising but maturing. Most RCTs are short-duration and use variable formulations.

Cannabinoid therapeutics appear to be a useful tool in a broader sleep toolkit — not a standalone fix. The gold-standard behavioral treatment for chronic insomnia remains CBT-I, and it works remarkably well even in digital formats. Exercise, sleep restriction therapy, and mindfulness meditation all have strong evidence bases. The most thoughtful clinical approach is additive.

Before starting any cannabinoid product for sleep, talk with your healthcare provider — especially if you're on other medications or have cardiovascular concerns. For clinician-reviewed education, dosing context, and third-party lab results, visit cannabisdnp.com/learn.

Jesse Cole Christianson, DNP, APRN, AGPCNP-BC, is a board-certified adult-gerontology primary care nurse practitioner and cannabinoid therapeutics educator.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Selected references: Luu et al., Sleep Medicine Reviews, 2025 · Walsh et al., Journal of Cannabis Research, 2023 · Mendiguren et al., Frontiers in Pharmacology, 2023 · Ranum et al., Cannabis and Cannabinoid Research, 2023 · Bhatt et al., Sleep, 2021 · Blessing et al., Neurotherapeutics, 2015 · Shannon et al., The Permanente Journal, 2019